Elevar Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2755 E Cottonwood Pkwy Ste 540, Salt Lak...Phone Number
(801) 303-7440Website
www.elevartherapeutics.comRevenue
$19.2 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Elevar Therapeutics
Elevar Therapeutics is a biopharmaceutical company dedicated to developing oncology therapeutics aimed at improving treatment experiences and outcomes for patients with limited options. Their focus is on advancing next-generation therapies that can set new standards of care across various health conditions. The company is committed to engaging ethically with patients, caregivers, and healthcare providers to address underserved needs. Elevar Therapeutics emphasizes collaboration within its skilled team to transform challenges into opportunities for the patients they serve.Explore more
Elevar Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elevar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Elevar Therapeutics has new funding data
Check out if Elevar Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Elevar Therapeutics recently announced quarterly report
Click to see if Elevar Therapeutics had a recent Job posting/layoffs
Check if Elevar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Elevar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Elevar Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Elevar Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Elevar Therapeutics
Compare insights from companies similar to Elevar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Elevar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Elevar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Elevar Therapeutics.
Elevar Therapeutics financials insights
Gather financial insights about Elevar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2021
Debt
$780K
Elevar Therapeutics Tech Stack
A closer look at the technologies used by Elevar Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves
Lateral Move
Executive Move
Executive Moves, Lateral Move
Open Position
Open Position
Elevar Therapeutics News & Media
Elevar Therapeutics to Share Camrelizumab/Rivoceranib Poster at International Liver Cancer Association Conference on Clinical Outcomes in Younger Age Patients with Unresectable Hepatocellular Carcinoma
BRUSSELS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced that in a post hoc analysis of its Phase 3 CARES-310 study, camrelizumab, an anti-PD-1 antibody, plus rivoceranib, an oral TKI, demonstrated a clinically meaningful progression-free survival (PFS) benefit across all age subgroups when compElevar Therapeutics Announces Three Abstracts Accepted for Presentation at ESMO Congress 2026
FORT LEE, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients with inadequate therapeutic options, today announced the acceptance of three abstracts for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, which will be held October 23-27 in Madrid.Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
FORT LEE, N.J., July 10, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding its new drug application (NDA) for the combination of rivoceranib, an oral TKI, and camrelizumab, an anti-PD-1 antibody, as a first-linElevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
FORT LEE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the first patients were dosed in its global Phase 2 study of lirafugratinib in non-cholangiocarcinoma (CCA) solid tumors with FGFR2 fusion or rearrangement.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elevar Therapeutics
Sign Up For FreeTo access detailed company insights
Elevar Therapeutics is a biopharmaceutical company dedicated to developing oncology therapeutics aimed at improving treatment experiences and outcomes for patients with limited options. Their focus is on advancing next-generation therapies that can set new standards of care across various health conditions. The company is committed to engaging ethi... Read More
